Skip to content
TrialScanner

NCT02912260

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Phase 2CompletedMDGLLead

Registry record

Lead sponsor
Madrigal Pharmaceuticals, Inc.
Conditions
Non-alcoholic Steatohepatitis
Primary completion
Oct 25, 2017Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02912260 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02912260: Phase 2 Study of MGL-3196 in... | TrialScanner